Fecal Microbiota Transplantation for Preventing Gastrointestinal Symptoms in Extrapulmonary Neuroendocrine Neoplasms: A Real-World Study

Inclusion criteria

• Age ≥18 years, regardless of gender;
• Anticipated survival period ≥3 months;
• Pathologically confirmed diagnosis of extrapulmonary neuroendocrine neoplasms;
• Development of gastrointestinal adverse reactions (including but not limited to diarrhea, constipation, vomiting, nausea, etc.) within three cycles of standard treatment;
• Patients are capable and willing to sign an informed consent form and complete follow-up;
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 1-3;
• No use of oral/intravenous broad-spectrum antibiotics within 3 days prior to enrollment;
• Ability to swallow capsules without chewing;
• Adequate organ function confirmed by screening laboratory tests.

Exclusion criteria

• Patients with major organ dysfunction or failure, including but not limited to cardiac insufficiency/heart failure, renal insufficiency/failure, or hepatic insufficiency/failure;
• Uncontrolled or severe infection;
• Known history of psychotropic drug abuse, alcoholism, or substance abuse;
• Severe infection accompanied by sepsis or septicemia;
• History of severe allergic reactions or known allergy to components of the liquid live bacterial enteric-coated capsules;
• Female subjects with a positive pregnancy test, lactating women, or women of childbearing potential who refuse to use contraceptive measures during the observation period (15 weeks);
• Patients with gastrointestinal perforation and/or fistula;
• Other conditions deemed unsuitable for enrollment by the investigator.